{"title":"提高生活质量","authors":"Katie Smith, P. Adams","doi":"10.1142/9789811216459_0008","DOIUrl":null,"url":null,"abstract":"• Increase of Operating EBITA with 22% to €66 million (Q3 2019: €54 million), resulting in operating margin of 10.9% (Q3 2019: 8.4%) • Excellent free cash flow of €119 million (Q3 2019: €4 million) • Strengthened balance sheet and successfully completed €150 million re-financing • Grown backlog with 4% compared to Q2 2020 and year-to-date 6% • Arcadis organization and business continues to proof resilience • Decision to significantly reduce footprint in the Middle East • Non-cash goodwill/intangibles impairment for Middle East and CallisonRTKL of €126 million","PeriodicalId":406241,"journal":{"name":"Fundamentals of Glaucoma","volume":"112 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"IMPROVING QUALITY OF LIFE\",\"authors\":\"Katie Smith, P. Adams\",\"doi\":\"10.1142/9789811216459_0008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"• Increase of Operating EBITA with 22% to €66 million (Q3 2019: €54 million), resulting in operating margin of 10.9% (Q3 2019: 8.4%) • Excellent free cash flow of €119 million (Q3 2019: €4 million) • Strengthened balance sheet and successfully completed €150 million re-financing • Grown backlog with 4% compared to Q2 2020 and year-to-date 6% • Arcadis organization and business continues to proof resilience • Decision to significantly reduce footprint in the Middle East • Non-cash goodwill/intangibles impairment for Middle East and CallisonRTKL of €126 million\",\"PeriodicalId\":406241,\"journal\":{\"name\":\"Fundamentals of Glaucoma\",\"volume\":\"112 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Fundamentals of Glaucoma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1142/9789811216459_0008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fundamentals of Glaucoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1142/9789811216459_0008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
• Increase of Operating EBITA with 22% to €66 million (Q3 2019: €54 million), resulting in operating margin of 10.9% (Q3 2019: 8.4%) • Excellent free cash flow of €119 million (Q3 2019: €4 million) • Strengthened balance sheet and successfully completed €150 million re-financing • Grown backlog with 4% compared to Q2 2020 and year-to-date 6% • Arcadis organization and business continues to proof resilience • Decision to significantly reduce footprint in the Middle East • Non-cash goodwill/intangibles impairment for Middle East and CallisonRTKL of €126 million